A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Hepatitis C
Interventions
DRUG

Peg-Intron

SC injection, weight based dosing, weekly, 48 weeks

DRUG

REBETOL

Capsules, weight based dosing, Q12 hrs daily, 48weeks

DRUG

HCV 796

Capsules, 500 mg, Q 12 hrs. daily, 48 weeks

DRUG

Peg-Intron

SC injection, weight based dosing, weekly, 48 weeks

DRUG

REBETOL

Capsules, weight based dosing, Q12 hrs daily, 48weeks

DRUG

HCV 796

Capsules, 500 mg, Q 12 hrs. daily, 48 weeks

DRUG

Peg-Intron

SC injection, weight based dosing, weekly, 48 weeks

DRUG

REBETOL

Capsules, weight based dosing, Q12 hrs daily, 48weeks

Trial Locations (35)

10021

Pfizer Investigational Site, New York

10032

Pfizer Investigational Site, New York

10461

Pfizer Investigational Site, The Bronx

10468

Pfizer Investigational Site, The Bronx

19141

Pfizer Investigational Site, Philadelphia

20010

Pfizer Investigational Site, Washington D.C.

22003

Pfizer Investigational Site, Annandale

22031

Pfizer Investigational Site, Fairfax

23249

Pfizer Investigational Site, Richmond

27710

Pfizer Investigational Site, Durham

30309

Pfizer Investigational Site, Atlanta

32610

Pfizer Investigational Site, Gainesville

33136

Pfizer Investigational Site, Miami

40202

Pfizer Investigational Site, Louisville

44195

Pfizer Investigational Site, Cleveland

45219

Pfizer Investigational Site, Cincinnati

48202

Pfizer Investigational Site, Detroit

55117

Pfizer Investigational Site, Saint Paul

55446

Pfizer Investigational Site, Plymouth

63104

Pfizer Investigational Site, St Louis

77030

Pfizer Investigational Site, Houston

87131

Pfizer Investigational Site, Albuquerque

90033

Pfizer Investigational Site, Los Angeles

91105

Pfizer Investigational Site, Pasadena

92037

Pfizer Investigational Site, La Jolla

92067

Pfizer Investigational Site, La Jolla

92123

Pfizer Investigational Site, San Diego

92161

Pfizer Investigational Site, San Diego

92801

Pfizer Investigational Site, Anaheim

94115

Pfizer Investigational Site, San Francisco

94121

Pfizer Investigational Site, San Francisco

02215

Pfizer Investigational Site, Boston

01655

Pfizer Investigational Site, Worcester

27599-7209

Pfizer Investigational Site, Chapel Hill

00909

Pfizer Investigational Site, Santurce

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ViroPharma

INDUSTRY

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00367887 - A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects | Biotech Hunter | Biotech Hunter